Shreya Goel is an Assistant Professor at the University of Utah , affiliated with the College of Pharmacy (Molecular Pharmaceutics) and the School of Medicine (Radiology and Imaging Sciences). Her research focuses on integrating molecular imaging , biologics engineering , and theranostics to develop innovative cancer therapies. PhD: University of Wisconsin-Madison Her work leverages positron emission tomography (PET) , optoacoustic imaging , and nanotechnology to visualize disease microenvironments, optimize radionuclide therapies , and enhance pharmacokinetic/pharmacodynamic modeling for drug development. Current projects include mitochondrial metabolism targeting in pediatric tumors, ultrasmall nanoprobes for surgical guidance, and hypoxia alleviation strategies in cancer treatment. Publications highlight advancements in imaging-guided radiotherapy , nanoprobe design , and multispectral optoacoustic tomography for tumor microenvironment analysis. Her lab actively recruits graduate students and postdoctoral researchers for interdisciplinary projects in pediatric oncology , radiopharmaceuticals , and biologics .
Lionel Hebbard is a Professor in the Department of Molecular and Cellular Biology at James Cook University's College of Medicine and Dentistry. His research spans hepatocellular carcinoma mechanisms, metabolic liver disease, and cancer therapeutics with significant contributions to adiponectin biology and sarcopenia assessment in cardiac surgery. James Cook University (Current) Department of Molecular and Cellular Biology College of Medicine and Dentistry Senior Researcher in Liver Cancer Biology His research focuses on hepatocellular carcinoma pathogenesis , particularly adiponectin signaling pathways and liver cancer stem cells. He investigates non-alcoholic fatty liver disease progression to cancer, metabolic drivers of tumorigenesis, and therapeutic targeting using aptamer-based delivery systems. Recent work explores sarcopenia quantification via CT imaging for cardiac surgery risk prediction, demonstrating clinical translation of his molecular findings. His lab employs advanced techniques including CRISPR screening (TARGET-SL platform), in vitro cancer models, and murine tumor systems. Analysis of his 15 most recent publications reveals strong emphasis on translational liver cancer research (60%), cardiac surgery complications (20%), and emerging biotechnologies (20%). Key trends include adiponectin's dual roles in fibrosis and tumorigenesis, sarcopenia as a surgical biomarker, and aptamer-based targeting of cancer stem cells. His work consistently bridges molecular mechanisms with clinical applications, particularly in hepatocellular carcinoma diagnostics and treatment. He mentors multiple doctoral students and early-career researchers including Rhys Gillman and Miriam Wankell. His research is supported by continuous funding from Australian NHMRC and international collaborations with George Jacob (Westmead Institute), Qiao Liang (Bentham Books), and Ranscht Barbara (T-cadherin studies). He leads the Hepatic Cancer Biology laboratory focusing on: Liver cancer stem cell characterization Adiponectin receptor signaling in HCC Metabolic drivers of tumor progression Novel drug delivery systems for liver cancer Translational sarcopenia assessment tools
Southern University of Science and Technology (SUSTech)China
Liu Hongmei is a Researcher and Master's Supervisor at Southern University of Science and Technology's Department of Biomedical Engineering. Holding a Ph.D. from the Chinese Academy of Sciences, she specializes in micro-nano robotics and tissue engineering for tumor therapy, with over 66 publications and 12 patents. Her work bridges biomedical engineering and nanotechnology for precision cancer treatments. B.S., Biological Sciences, Harbin Normal University (2005) M.S., Botany, Northeast Agricultural University (2008) Ph.D., Biochemical Engineering, Chinese Academy of Sciences (2015) Her research focuses on biomaterials engineering , nanoparticle drug delivery , and microenvironment-responsive hydrogels . Key areas include glioma therapy, traumatic brain injury recovery, and intervertebral disc degeneration treatments. Recent work explores pH/ROS/inflammation-triggered hydrogels and bioengineered bacteria for disease modulation. Article trends show a strong emphasis on nanoparticle design (2014-2025) for glioma, hydrogel development (2017-2025) for tissue repair, and biomimetic material synthesis (2023-2025) inspired by spider silk and meniscus structures. Sub-fields span pyroptosis inhibition, epigenetic reprogramming, and microbiome engineering. Jiangsu Science and Technology Award (2020) Jiangsu Medical Science and Technology Award (2020) Jiangsu Educational Science Research Award (2021) Chinese Medical Doctor Association's Outstanding Young Scientist (2018) Liu has supervised numerous projects including National Natural Science Foundation of China grants, Jiangsu Province Key R&D Program funding, and Shenzhen City General Projects. She holds 12 Chinese invention patents and collaborates with institutions like the UNESCO Centre for Higher Education Innovation.
Dong-Hyun Kim, PhD, is a Professor at the Feinberg School of Medicine and McCormick School of Engineering at Northwestern University. His research focuses on developing therapeutic micro/nanoparticles for cancer treatment, including drug delivery, hyperthermia, immunotherapy, and molecular imaging. He collaborates with clinicians, biologists, and imaging professionals to translate multifunctional carriers into clinical applications. Education: PhD: Yonsei University College of Medicine, Korea (2006) Postdoctoral Fellow: University of Alabama, Chemical & Biological Engineering (2008) Postdoctoral Fellow: Argonne National Laboratory, Materials Science Division (2011) Research Interests: Therapeutic carriers for cancer treatment (e.g., nanoparticles, microspheres) Interventional oncology and targeted drug delivery Immunotherapy integration with nanotechnology Diagnostic imaging (MRI, CT, ultrasound) for treatment monitoring Translational research bridging lab and clinical applications Key Trends in Publications: Recent work emphasizes CRISPR-mediated genome editing, ferroptosis-inducing nanoparticles, cryo-immunotherapy, and radiomics for tumor assessment. Articles highlight synergy between nanotechnology and immunotherapy, with a focus on liver, prostate, and pancreatic cancers. Affiliations: Northwestern University Clinical and Translational Sciences Institute (NUCATS) Robert H. Lurie Comprehensive Cancer Center Labs/Teams: Active in multidisciplinary teams developing nanomedicine and interventional oncology therapies, leveraging Northwestern’s clinical and engineering resources.
Dr. Magdy Salama is a Professor in the Department of Electrical and Computer Engineering at the University of Waterloo, with dual professional engineering registrations in Ontario and Egypt. His research focuses on power systems, smart grid technologies, renewable energy integration, and medical imaging. He holds over 460 publications, including 215 journal articles, and has developed specialized labs in areas like Power Quality and Ultrasound Imaging. Recognized in the 1991 National Encyclopedia of Egyptian Scientists, he also teaches courses such as ECE 192, 390, and 462, emphasizing engineering economics and design. Education: PhD, Electrical Engineering, University of Waterloo (1977) MSc, Electrical Engineering, Cairo University (1973) BSc, Electrical Engineering, Cairo University (1971) Research Interests: Power quality and distribution system automation Smart grid and renewable energy analysis Medical image processing (e.g., sleep staging, neuromodulation) Electric energy storage and fault detection Asset management and risk analysis Labs & Innovation: He leads labs in Power Quality, Electric Vehicle Power Electronics, Ultrasound Imaging, and Sleep Staging. His patents include high-voltage power supplies for automotive and aerospace applications. Awards: Listed in the 1991 National Encyclopedia for Distinguished Egyptian Men of Science . Teaching & Grants: Recently taught courses like Distribution System Engineering (ECE 6606PD) and Electric Safety Design (ECE 6616PD). His work spans academic-industrial partnerships, though specific grants are not detailed in the text.
Marta Marques Alves is an Assistant Professor at the Instituto Superior Técnico (IST) , University of Lisbon, affiliated with the Centro de Química Estrutural (CQE) . She holds a PhD in Plant Biochemistry (2010) from the New University of Lisbon (UNL) and has been a Junior Researcher in Materials Sciences at IST since 2018. Her research focuses on functional materials , particularly zinc-based biomaterials for biomedical applications , such as 3D-printed bone scaffolds that degrade naturally and release therapeutic agents. She bridges plant science and materials engineering, emphasizing eco-conscious solutions for societal transitions. She teaches Industrial Safety and Utilities and Mass and Energy Balances . Her editorial roles include serving on the boards of Scientific Reports , Applied Surface Science Advances , and Surfaces and Interfaces . She coordinates the Corrosion Science and Surface Engineering (CSSE) research group (20 members) and serves on CQE’s executive committee. Her work has led to over 50 peer-reviewed publications and collaborations in national and international projects. Institutional contributions include advising graduate students and overseeing research infrastructure. Her outreach efforts include a podcast explaining her innovations in biocompatible materials. She advocates for sustainable materials and interdisciplinary research, addressing challenges in healthcare and environmental science.
Radu O. Minea is an Assistant Professor of Research in Neurological Surgery at the University of Southern California (USC). His research focuses on developing conjugated drug therapies for cancers such as glioblastoma, leukemia, and lymphoma. He specializes in preclinical models to evaluate the efficacy of novel compounds like NEO212, NEO214, and NEO100, which target cancer cells through mechanisms including autophagy inhibition, macrophage differentiation, and enhanced drug delivery to tumor sites. His work bridges molecular oncology, drug design, and translational medicine, with a particular emphasis on overcoming drug resistance in malignant tumors. Key research areas include: Design and testing of conjugated chemotherapeutic agents Mechanisms of drug resistance in gliomas and hematologic malignancies Targeted drug delivery strategies for brain-localized cancers Role of disintegrins and venom-derived peptides in cancer therapy Dr. Minea’s publications highlight innovations in radiosensitization, antiviral cancer therapies, and the application of multi-integrin targeting proteins. His research has implications for improving treatment outcomes in aggressive cancers like glioblastoma and acute myeloid leukemia.
Prof. Dr. Verena Jendrossek is a full Professor and Chair of Cell Biology at the Institute of Cell Biology (Tumor Research), Faculty of Medicine, University of Duisburg-Essen. She also serves as Deputy Managing Director and leads research in molecular and experimental radiooncology. Her group is deeply integrated into the ZMB (Center for Medical Biotechnology) and participates in DFG Research Training Group 1739. Institution: University of Duisburg-Essen School: Faculty of Medicine Department: Institute of Cell Biology (Tumor Research) Leadership: Chair of Cell Biology, Deputy Managing Director Her research focuses on the molecular mechanisms of therapy-induced cell death, tumor resistance, radiation-induced immune changes, and normal tissue toxicity. Her work spans molecular cell biology, radiation biology, and experimental radiooncology , with emphasis on identifying biomarkers and developing novel therapeutic strategies. She investigates the PI3K pathway and microenvironmental influences on treatment response. The recent publications highlight a strong trend in radiation biology, cancer metabolism, autophagy regulation, and immunomodulation post-radiotherapy. Her team explores radiosensitization strategies , metabolic rewiring , and fibrosis mechanisms , often using preclinical models including in vitro , in ovo , and in vivo systems. Collaborative clinical studies in lung cancer are also prominent. Scientific awards are not listed in the provided text. Prof. Jendrossek supervises a large team of doctoral students across medical and scientific disciplines. She leads junior research groups and collaborates with clinical research teams for translational validation of therapeutic approaches. No specific grant information is mentioned, but her involvement in DFG Research Training Group 1739 indicates active funding. She supports a collaborative research environment with structured mentoring. The research group operates within the ZMB and includes junior group leaders such as Dr. Florian Wirsdörfer, PD Dr. Justine Rudner, Dr. Silvia Vega Rubin de Celis, PD Dr. Johann Matschke, and Dr. Farnoush Farahpour. The lab also hosts the Laboratory for Vascular Remodeling led by apl. Prof. Dr. Diana Klein. The team comprises multiple postdocs, doctoral students, and technical staff, indicating a highly active and multidisciplinary research environment.
Dr. Michal Heger is a Researcher at Utrecht University's Faculty of Science, specifically within the Membrane Biochemistry & Biophysics department. He also holds the position of Professor of photonanomedicine at Jiaxing University Medical College in China and serves as Editor-in-chief of the Journal of Clinical and Translational Research. Additionally, he is Chief formulation officer at Nurish.Me in San Diego. Dr. Heger's research primarily focuses on the development of minimally invasive diagnostic and therapeutic modalities for treatment-resistant cancers, with special emphasis on bile duct cancer (extrahepatic cholangiocarcinoma, eCCA). His work follows three pillars: minimally invasive approaches, patient-friendly treatments, and affordable solutions. Photodynamic therapy (PDT) forms the core of his research program, where he investigates nanoscale carrier platforms for photosensitizer delivery, cancer cell responses to PDT, PDT-induced immune responses, and representative cell and animal models for cholangiocarcinoma. His publication record shows significant expertise in photodynamic therapy, with numerous articles spanning from 2012 to 2025. The research trends indicate a strong focus on nanotechnology applications in cancer therapy, particularly in developing targeted delivery systems for photosensitizers and combination therapies. His work bridges basic science with clinical applications, especially in difficult-to-treat cancers where conventional approaches have limited success. Dr. Heger collaborates extensively with various research groups, particularly in the areas of liquid biopsies and molecular profiling for cancer diagnostics and therapy monitoring. His work often involves interdisciplinary approaches combining pharmacology, nanotechnology, and molecular biology to address challenging clinical problems in oncology.
Md Sahadat Hossain is a researcher at the Faculty of Science and Engineering , Macquarie University , specializing in entomology and natural product chemistry with a focus on biopesticide development , insect behavior studies , and environmental toxicology . He previously held academic roles at the University of Rajshahi in zoology and crop protection . Education Doctor of Philosophy (PhD), Macquarie University (2022–2025) Master of Research (MRes), Macquarie University (2021–2023) Master of Science (MS), University of Rajshahi (2016–2018) Bachelor of Science (BSc), University of Rajshahi (2012–2016) His research explores plant-based alternatives for pest control, including essential oils , leaf extracts , and radiosensitivity in insect pupae . He has published extensively on topics like Queensland fruit fly behavior , stored product pest management , and chemical ecology of agricultural pests. Publications span peer-reviewed journals such as the Journal of Chemical Ecology , Journal of Pharmacognosy and Phytochemistry , and Journal of Entomology and Zoology Studies . Key themes include bioassays , insecticide development , and eco-friendly pest management . Scientific Awards Bangabandhu Gold Medal, Agrani Bank (2023) Best Poster Presentation Award (2017) Champion of Zoology Olympiad (2015) International Macquarie University Research Excellence Scholarship (iMQRES) for PhD (2023) iMQRES for MRes (2021) He is a member of the International Society of Chemical Ecology (ISCE) (2025–2025). His work bridges experimental design , toxicology , and ecological research to address sustainable agriculture challenges.
Cristina Espinosa-Diez, PhD is an Assistant Professor of Molecular Medicine and Genetics and of Physiology at Wayne State University's School of Medicine in Detroit, Michigan. Her research focuses on understanding how cancer therapies shape the epigenetic landscape of vascular cells, potentially giving rise to long-term vascular complications through non-coding RNA mechanisms. Education PhD in Molecular Biology and Biomedicine from University Complutense, Madrid, Spain (2015) Postdoctoral researcher at Oregon Health and Science University (2015-2019) Postdoctoral fellow at University of Pittsburgh's Vascular Medicine Institute (2019-2023) Dr. Espinosa-Diez leads a non-coding-RNA laboratory investigating the response of long-non-coding RNAs to different anti-cancer agents and their role in vascular remodeling during disease progression. Her work integrates molecular biology, epigenetics, and vascular biology to understand how cancer treatments impact vascular health, with particular focus on microRNAs and their regulatory functions in endothelial and smooth muscle cells. Her research spans from basic mechanisms of epigenetic regulation to translational applications in cancer therapy complications. Analysis of her recent publications reveals a strong focus on non-coding RNA regulation in vascular biology, particularly examining how microRNAs and long non-coding RNAs influence smooth muscle cell phenotype, endothelial function, and vascular responses to stressors like radiation and metabolic syndrome. Her work demonstrates how epigenetic modifications, particularly histone methylation and non-coding RNA expression, govern vascular cell identity and function in both health and disease contexts. Scientific Awards American Heart Career Development Award Dr. Espinosa-Diez established her independent research program at Wayne State University in October 2023 after completing her postdoctoral training. Her laboratory investigates the intersection of cancer therapy, epigenetics, and vascular biology, with particular emphasis on understanding how treatments like radiation impact vascular cells through non-coding RNA mechanisms. She maintains active collaborations with researchers at multiple institutions and has developed a productive publication record spanning basic molecular mechanisms to potential clinical implications. Though currently not accepting new graduate students for 2025/2026, she has previously mentored students and postdoctoral researchers in her field. The Espinosa-Diez Lab functions as an interdisciplinary research team employing molecular, cellular, and epigenetic approaches to understand vascular complications associated with cancer treatments. The laboratory investigates how non-coding RNAs mediate the vascular side effects of cancer therapies, with potential implications for developing strategies to protect vascular health during oncological treatment.
Helen Townley is an Associate Professor at the University of Oxford's Engineering Science Department and a Williams Fund Research Fellow. She also serves as a Senior Visiting Research Fellow in Engineering Science and an Associate Editor for Micro and Nano Letters. Her work focuses on nanoparticle-based therapies for cancer, drug delivery systems, and natural product applications in medicine. She holds a BSc (Hons) and PhD in relevant fields. Research Interests: Nanoparticle Cancer Therapy , Enhanced Drug Delivery , and Natural Product Chemotherapy . Her lab explores nanoparticle-mediated drug delivery, chemoembolization, and radiosensitization, with applications in glioblastoma and thalassemia treatment. Collaborations include projects on infertility and antimicrobial biocides. Recent Publications Highlight nano-theranostics , targeted drug delivery, and nanoparticle toxicity studies. Notable awards include the Kajal Mallick Memorial Award (2016) and recognition in BioBeat's '50 Movers and Shakers in BioBusiness 2016'. Advising and Grants: Supervises current and past students (e.g., Jasmine Liu, Ben Gaunt), and collaborates with global teams (e.g., Prof. Robert Kiss). Supported by the Williams Fund and other grants. Lab members include researchers and artists-in-residence.
Dr. Steven Petit is a Researcher in the Radiotherapy department at Erasmus MC. His research focuses on advanced radiation therapy techniques, imaging systems optimization, and radiation-induced toxicity prediction. Key areas include prostate and lung cancer treatment planning, CBCT imaging accuracy, and HPV-related oropharyngeal carcinoma diagnostics. Recent work explores ex vivo functional assays for mucosal toxicity prediction and MRI-based cancer subtype differentiation. He contributed to a European Society of Radiotherapy and Oncology mentoring program evaluation, emphasizing professional development initiatives in oncology. Collaborations span multidisciplinary teams in molecular biology, radiology, and clinical oncology. His research outputs include 72 publications with recent emphases on radiation dosimetry, imaging technology advancements, and translational research in cancer treatment.
Devika Chithrani is Professor in the Department of Physics and Astronomy at the University of Victoria's Faculty of Science, leading pioneering research in cancer nanomedicine using gold nanoparticles to enhance radiotherapy and chemotherapy while reducing normal tissue toxicity. Education: PhD, University of Toronto, Canada MSc, University of Toronto, Canada BSc (Hons), University of Colombo, Sri Lanka NSERC Postdoctoral Fellow, University of Toronto, Canada Her research focuses on nanoparticle synthesis/characterization, radiosensitizer development, and multimodal imaging systems. She investigates how nanoparticle size, shape, and surface properties dictate intracellular fate in vitro and in vivo, engineering 3D tissue-like models to optimize therapeutic platforms. Her work bridges fundamental bio-nano interface studies with clinical translation for improved cancer diagnostics and treatment. Publication trends from 2006-2022 reveal progression from foundational nanoparticle-cell interaction studies to advanced tumor microenvironment applications and combination therapies (e.g., gold nanoparticles with pyronaridine/bleomycin), demonstrating translational momentum toward clinical implementation in radiation oncology. Scientific awards: NSERC Postdoctoral Fellow She mentors 5 current graduate students (including NSERC-funded PhD candidates Nolan Jackson and Daniel Cecchi) and has supervised 10+ previous students who received prestigious awards like NSERC CGS D and UVic Fellowships. Her research is funded by CIHR, NSERC, Mitacs Accelerate, CFI, BCKDF, and the Government of Canada's NCE Program. She directs the Nanoscience and Technology Laboratory, a multidisciplinary team integrating physics, chemistry, biology, and computer science to develop nanomaterials (gold/lipid nanoparticles) that enhance radiotherapy/chemotherapy efficacy through precise tumor targeting and reduced systemic toxicity.
Devid Maniglio is an Associate Professor at the Department of Industrial Engineering, University of Trento. His research focuses on bioengineering, biomaterials, and tissue engineering, with a particular emphasis on bioprinting, surface modification, and functional materials. He has contributed to advancements in silk fibroin and hydrogel-based systems for medical applications. Research Interests Bioengineering for personalized medicine Biomaterials and surface engineering 3D bioprinting and tissue regeneration Molecular imprinting and biosensors Drug delivery and cell encapsulation Teaching Diagnostic and therapeutic technologies for personalized medicine Engineered materials for precision medicine Fundamentals of biomedical technologies Functional surfaces laboratory Labs & Collaborations Devid Maniglio is affiliated with the Functional Surfaces Laboratory at the University of Trento, collaborating with researchers such as Stefano Rossi and Flavio Deflorian. His work integrates interdisciplinary approaches in biomedical engineering and sustainable medical technologies.
